Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services.
Affiliation
1INSERM U379, Epidemiology and Social Sciences Applied to Medical Innovation, Institut Paoli-Calmettes, Marseille, France. julian@marseille.inserm.frIssue Date
2003-10
Metadata
Show full item recordAbstract
The objective of this paper is first to describe the different strategies used to communicate risks to patients in the field of cancer or genetics, to review their effectiveness, and to summarise the state of the art of this practice in particular, in cancer genetics. The target audience is health care professionals involved in the communication of cancer risks, and genetic risks of breast/ovarian or colorectal cancer in particular. The methods include a review of the literature (Medline, Pascal, PsycInfo, Embase) by a panel of researchers and clinicians (cancer geneticists, epidemiologists, health psychologists, sociologists) in the context of a European Project on risk communication. We highlight practices that have been shown to be effective in the context of health psychology research and those being still under consideration for use in routine practice. In conclusion, this paper adds clinical relevance to the research evidence. We propose specific steps that could be integrated in standard clinical practice based on current evidence for their usefulness/effectiveness.Citation
Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. 2003, 11 (10):725-36 Eur. J. Hum. Genet.Journal
European Journal of Human GeneticsDOI
10.1038/sj.ejhg.5201037PubMed ID
14512961Type
ArticleLanguage
enISSN
1018-4813ae974a485f413a2113503eed53cd6c53
10.1038/sj.ejhg.5201037
Scopus Count
Collections
Related articles
- Psychosocial impact of the lack of information given at referral about familial risk for cancer.
- Authors: Metcalfe A, Werrett J, Burgess L, Clifford C
- Issue date: 2007 May
- Cancer genetics in primary care.
- Authors: Culler D, Grimes SJ, Acheson LS, Wiesner GL
- Issue date: 2004 Sep
- A literature review of the psychological impact of genetic testing on breast cancer patients.
- Authors: Schlich-Bakker KJ, ten Kroode HF, Ausems MG
- Issue date: 2006 Jul
- Genetics and the multidisciplinary breast center.
- Authors: Peters JA, Rubinstein WS
- Issue date: 2000 Apr
- Genetic testing for hereditary cancers: the impact of gender on interest, uptake and ethical considerations.
- Authors: d'Agincourt-Canning L, Baird P
- Issue date: 2006 May
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)